We talked to AdAlta CEO Dr. Tim Oldham about the conversion of the lead I-body product AD-214 to nebulised delivery and about the major upside from the GE Healthcare collaboration.
Stocks Down Under … Serious research for the serious investor!
Get Marc & Stuart’s Top Picks
Improve your investment skills with our Investor Webinars
Learn about ASX-listed stocks with our 4 editions per week across all sectors
Get access to everything with a 30-day FREE TRIAL.
No credit card required!
